Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.

Wilcox CS, Oskooilar N, Erickson JS, Billes SK, Katz BB, Tollefson G, Dunayevich E.

Addict Behav. 2010 Mar;35(3):229-34. doi: 10.1016/j.addbeh.2009.10.017. Epub 2009 Oct 31.

PMID:
19926400
2.

A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.

O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P.

Arch Intern Med. 2006 Mar 27;166(6):667-74.

PMID:
16567607
3.

A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.

Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS.

Addict Behav. 2008 Jan;33(1):173-9. Epub 2007 Jun 2.

4.

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.

Tønnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, Townsend J.

J Intern Med. 2003 Aug;254(2):184-92.

5.

[Preventing weight gain in smoking cessation: there is no miracle solution].

Nanchen D, Willi C, Peytremann-Bridevaux I, Burnand B, Walther MR.

Rev Med Suisse. 2009 Aug 5;5(212):1577. French. No abstract available.

PMID:
19728455
6.

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB.

N Engl J Med. 1999 Mar 4;340(9):685-91.

7.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
8.

A comparison of sustained-release bupropion and placebo for smoking cessation.

Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM.

N Engl J Med. 1997 Oct 23;337(17):1195-202.

9.
10.

Abstinence rates and predictors of outcome for smoking cessation: do Brazilian smokers need special strategies?

Chatkin JM, Mariante de Abreu C, Haggsträm FM, Wagner MB, Fritscher CC.

Addiction. 2004 Jun;99(6):778-84.

PMID:
15139876
11.

Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.

Chengappa KN, Kambhampati RK, Perkins K, Nigam R, Anderson T, Brar JS, Vemulapalli HK, Atzert R, Key P, Kang JS, Levine J.

J Clin Psychiatry. 2001 Jul;62(7):503-8.

PMID:
11488359
12.

Outcomes from an outpatient smoking-cessation clinic.

Roth MT, Andrus MR, Westman EC.

Pharmacotherapy. 2005 Feb;25(2):279-88.

PMID:
15767242
13.

Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies.

Saxon AJ, Baer JS, Davis TM, Sloan KL, Malte CA, Fitzgibbons K, Kivlahan DR.

Nicotine Tob Res. 2003 Aug;5(4):589-96.

PMID:
12959797
14.

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.

J Clin Psychopharmacol. 2007 Aug;27(4):380-6.

PMID:
17632223
15.

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.

Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J.

Nicotine Tob Res. 2001 May;3(2):131-40.

PMID:
11403727
16.

Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia.

Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC.

J Clin Psychiatry. 2005 Sep;66(9):1184-90.

PMID:
16187778
17.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
18.

The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation.

Walsh Z, Epstein A, Munisamy G, King A.

J Addict Dis. 2008;27(1):65-72. doi: 10.1300/J069v27n01_07.

PMID:
18551889
19.

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.

Clin Ther. 2001 May;23(5):744-52.

PMID:
11394732
20.

Smoking cessation treatment in a real-life setting: the Greek experience.

Rovina N, Nikoloutsou I, Dima E, Michailidou M, Roussos C, Gratziou C.

Ther Adv Respir Dis. 2007 Dec;1(2):93-104. doi: 10.1177/1753465807085799.

PMID:
19124351

Supplemental Content

Support Center